Chuck, you, good Thank morning, and everyone.
provide in return I remarks, to sustained of following had offset pipeline, markets and will my I both the the year, the the impact of up a a starting the decreases then product the in fourth in saw key PEH Hospira PIH the that emerging another due also strong our financial X% primarily of each advancement selling Pfizer Established including: our billion at growth, the the continued our X% XXXX. Lyrica growing in and brands, growth impact markets. strength primarily $X.X with will negatively transferred During portfolio, XXXX. XXXX to few performance Health. performance Ibrance, will Revenues several several in Innovative of operationally, and portfolio our from biosimilars. for I and put with in Legacy medicines Injectables the approximate. LOE to Frank in thanks to Pfizer solid in Viagra increases This shortages continued year speak These begin biggest regarding in another impacts as guidance. well vaccines and about for businesses, were beginning of our markets We Prevenar in remind of quarter top-line and have partially U.S. XXXX. XX that Eliquis you to emerging XXXX globally; would our strategy Sterile in period as our of Products the words we of continued Xeljanz business continued developed year place its growth and details were and LOE the regarding the had year, Pfizer will legacy by in
So calculation, the if the would Viagra operationally. you from been have growth X% exclude
kept Many billion, of For or $X.X approximately receiving which XX% full operationally, in in with a endocrine combination therapy. Ibrance are increase inhibitor XX% year XXXX, revenues of while endocrine were an CDK U.S. chemotherapy. monotherapy patients represented still eligible are
advantage, educate the first-mover benefits XXX,XXX its We patients continue prescribed the most since community significant We Ibrance's strength of remain in of the experience the medicine more continued Ibrance our the confident launch. oncology data, class. about patient positive They're the in on based worldwide to therapy. importantly, with leadership and than
the in these competition current class of reimbursement And growth the of greater markets. developed here. outside another and Ibrance quarter U.S., Japan. than key developed volume has in driver in despite and CDK Europe international total markets, growth has majority Ibrance of particularly we maintained XX% increasing solid Our remains of for had achieved
$X up our on income XX% full when in sales in royalty For U.S. ex-U.S. alliance the Xtandi, And billion combined our were revenues nearly with for year. XXXX. the totaled
metastatic made the July Xtandi. an castration nonmetastatic indication cancer. urologists and approval, for number increased our continuing expanded prescribing cancer first approved in of prostate the the And U.S., of are only to both, medication the following nonmetastatic see it FDA prostate We in launch and resistant oral
Astellas, X survival December, and throughout met Xtandi progression-free both we These along cancer moving announced improving ADT treatment demonstrating its plus we trial endpoint, data Xtandi radiographic alliance alone. primary the into Xtandi generic. focused men ARCHES value significantly of the see growth prostate competition, from year. in versus branded In the hormone-sensitive earlier ADT partner, remain to metastatic And in that continued settings. We further with evaluating differentiate this with Xtandi Phase on our
We are for we oncology of authorities regarding confident of to of the will health years engaging Xtandi that global for an indication the Xtandi. in pillars expanded potential one And discussions come. our remain be portfolio
this revenues Xeljanz increasing to billion. year, with a tremendous XX% performance had For operationally $X.X
and as for contributions prescriptions, expansion pattern in with these prior growth of arthritis the drug's up a particularly scripts more We as year, forward had rheumatoid fourth XXXX, compared quarter. alliance Eliquis by revenue direct meaningful quarter into and in Our extremely XX% colitis. billion. the year ulcerative contributors indications colitis. This ulcerative increased even in growing operationally strong look sales performance from new with continued to arthritis XX% Xeljanz results well to driven continued strong another was recent psoriatic becoming $X.X with
year, Healthcare create operationally revenues totaling consumer December, healthcare the with we definitive Lastly, new into we which a venture. X% In agreed with grew have billion. our joint to business for under entered agreement Consumer a $X.X GSK,
in XXXX, subject We course expect regulatory required second customary half approval the approvals. and shareholder of to transaction including GSK of the to closing close conditions
for markets growth portfolio. revenues to and business in grew operational Emerging the Essential XX% for billion. to for now saw in revenue Turning year Pfizer markets again both Health, operationally the $X.X declined, the strong once emerging year, biosimilars our while we
Sterile Norvasc, emerging also were: operationally. XX% up Some up XX% biggest in markets drivers of operationally; Lipitor, growth and XX% the Injectables, up operationally;
our more grew constraints for Legacy Established Injectables up PEH XXXX. for in impact Our business product we the potential business, the additional revenues [Technical and XXXX in biosimilars and manufacturing In was Products the U.S. by for shortages business. see to lower supply than in markets Injectables Sterile offset X developed portfolio markets our biosimilars continue approvals in in FDA approvals supply Sterile top-line. emerging in in biosimilars to to approximate growth received XXXX operationally XX% Difficulty]. X We
and significantly growth of to business solid We the a this expect to continue expect be these future. issues in improved the to XXXX, contributor be end by
Group, organized As Hwang; three businesses: earlier. XX Slager, generic as of and branded into most and is an of Michael our led Pfizer headquartered aware, to markets Healthcare innovative XXXX iconic Upjohn, that by Angela off-patent is are venture preparing medicines business, world; is Pfizer of more and the business, fiscal start in a Consumer by Biopharmaceuticals now brands business, medicines I you science-based bringing led of the China Chris our our Goettler become the than to led XXX by around joint mentioned part year, which
panning to four new over targeted broader This pipeline In and of approvals we total, patient four the months from including cancer will our my pipeline. both of approvals a us received Now attention year extensions, last line a wave population. entities turn in agents to allow let our R&D me key we which molecular new XXXX. serve seven XXXX, saw
recent for In we our date of treatment FDA third me on touch for tafamidis In of key terms some rare achieved news, the ATTR-cardiomyopathy have NDA disease, our since of July. the in let with PDUFA accepted the filings milestones quarter call. a
In positive We been biosimilar third-generation we promising approved ATTR-cardiomyopathy making reminder, for received potential an CHMP there disease, Oncology patients the have Lorbrena, inhibitor for are diagnosed. biosimilar FDA treatments estimate several currently, opinion In underserved a for a cancer, developments. And a lung it Oncology, less this received market. leukemia. X% Daurismo for space, and incredibly no than of have we Zirabev, to for for we myeloid a ALK approvals Avastin. acute As
CDK a a tumor we've have second started pivotal studies. trial for Phase Medicine, major milligram and for Pfizer morning milligram started or for in line Phase from initiated Xb/X JAKX XX-valent moderate-to-severe clinical studies our solid alopecia X patients study conjugate cancer top our osteoarthritis X Immunology, a tanezumab types, In we trial. Phase Eli and pain. adults second We cancer Internal a Lilly evaluating Ibrance-resistant our for inhibitor results with Vaccines, generation & advanced X older. pneumococcal positive a announced areata and into Inflammation next clinical in vaccine applicable inhibitor partner moderate-to-severe for vaccine XX X.X this In In
combination potential the as further inflection for bevacizumab, for trastuzumab, taken to which rituximab first biosimilars, Pfizer. up XXXX that adalimumab, opportunity line and potential pipeline. blockbuster will in well for renal a several our for carcinoma Bavencio Inlyta These when we ahead, for points potential four of cell Looking include U.S. as approvals together see a advance and represent
address era Phase Thanks but view also to as significant line as rivipansel with million top of dermatitis chronic following We X expect of three positive time. believe we XX in with disease as we well unmet readouts to intersecting more low to than million trends the expect achievements these serious of growth and expected pain. Lyrica to rate, this the for readouts living an needs sickle are X what because more the the in suffering JAKX has well-positioned, XX than cell back we and and potential We Americans osteoarthritis LOE. for for very opportunity, become the Phase atopic line same are tanezumab, the leverage extremely which the at further growth bottom impact our a milestones, sustained
emerging First, macro the people trends such established and number markets a seeking to and of middle population increasing access medicines. class innovative rising both aging in as an
in the after LOEs believe continued to we breadth the Lyrica, benefits good best the with finally, and is next pipeline strong And what until the a history expect second Second, dramatic of decade. our of advancement the enjoy abatement in of innovation. half we
Our necessary the pivot course, to to stay growth. job steps to now is take the
our be This issues. We affordability organizational taken right place structure significantly we for that operational strategy capacity right innovation Deliver to effectiveness creating must words: up summed for resources improve steps and patient and innovating we Our the in current the standards these are means, have areas. and create doing have so that focused scientific addresses for and we ensure, value in of that three work. innovations, in advance both innovation access improves care growth. commercial can
We them. have our to operations simplify reorganized
and to and by capital be the in significantly actually with effort more lower aggressively increase within be growth This We automate significant our physician are which enterprise R&D, up experiences digital patient strategic planned the And drivers robotics technology are would anticipated reallocated includes simplify R&D. processes. entire enterprise-wide reducing leverage to costs profitable indirect much and down. resources initiating and come of access investing in overhead in And development, drug to speed will and spending areas importance. of an related project enhance to in reallocating in SI&A across spending, reductions we
we of addition, this, of dividend the investment our additional We growing shareholder-friendly a capital of thesis. as initiatives. to see course, continue part financial In an flexibility important to all have undertake allocation to
acquisitions type ability initiatives. repurchases or we appropriate licensing current share for that be as focusing the also on smaller development deploy capital tuck-in in time, We business would the have and to whether areas, other At opportunities compounds. mid-stage are
course, turn we for and are shareholder value. can doing and that patients, our our is and ecosystem accelerated XXXX. In ensure business enhanced patients without remain benefit achieve of Most continue in our provide for a players into and deliver summary, marketplace, we growth governments, our outlook other in challenges. to well-positioned isn't to focus, over that all All need profile our I we significantly, company rewarded taking to patients. to the and lives. believe affordable us to for with in it we we further growth designed payers, policymakers, and industry Frank more to steps enable pro-innovation quarter to we on see we for the for change and access advocate with the medicines now the health breakthroughs to its risk-taking that care to Of innovation while delivering policies ensure Frank? purpose new whole. this At create end, improved work company, our our the as are patients' will details clearly future
